Open an account

Entrada Therapeutics

TRDA · NASDAQ

$4.99+$0.17 (+3.53%)TodayMarket closed ·
Prev close $4.82

About TRDA

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2021-10-29. The firm is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The firm is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The firm has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Employees
152
Headquarters
Boston, Massachusetts
Listed
Oct 29, 2021
Sector
Health Care
Industry
Biotechnology
Website
entradatx.com

TRDA key statistics

Market cap
194.29M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
362.91K
Volume
403.07K
Open price
$4.81
High today
$5.27
Low today
$4.79
52 Week high
$16.45
52 Week low
$4.11

Entrada Therapeutics (TRDA) at a glance

Entrada Therapeutics (TRDA) last traded at $4.99, with a market cap of 194.29M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.79 and $5.27. The current price is 4.2% above the day's low and 5.3% below its high.

Volume so far is 403.07K shares, in line with the average of 362.91K shares a day.

Over the past year Entrada Therapeutics has ranged from $4.11 to $16.45, and now sits 7% of the way up that range.

Entrada Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.01 per share against an estimate of -$1.07.

The average analyst price target is $16.98, 240.3% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $16.98
Low
$7.31
Now
$4.99
High
$26.25

TRDA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 40.1% on average.

  1. Q3 FY24: reported -$0.35 per share against an estimate of -$0.7426
  2. Q4 FY24: reported $0.03 per share against an estimate of -$0.6832
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.8048
  4. Q2 FY25: reported -$1.04 per share against an estimate of -$0.8645
  5. Q3 FY25: reported -$1.06 per share against an estimate of -$0.9588
  6. Q4 FY25: reported -$0.94 per share against an estimate of -$1.17
  7. Q1 FY26: reported -$0.95 per share against an estimate of -$1.06
  8. Q2 FY26: reported -$1.01 per share against an estimate of -$1.07

TRDA news

  • Vandana Singh

    What's Going On With Entrada Therapeutics Stock Wednesday?

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

  • Press releaseGlobe Newswire

    TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

  • Avi Kapoor

    Dow Dips 350 Points; US Foods Posts Downbeat Earnings

  • Vandana Singh

    Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Similar companies

Companies in the same industry as Entrada Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.